Alphatec (NASDAQ:ATEC) Director David Demski Sells 30,000 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) Director David Demski sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $21.20, for a total value of $636,000.00. Following the completion of the sale, the director directly owned 399,623 shares of the company’s stock, valued at approximately $8,472,007.60. This represents a 6.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Alphatec Trading Up 0.3%

ATEC stock opened at $19.96 on Friday. The company has a market capitalization of $2.97 billion, a PE ratio of -19.19 and a beta of 1.08. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99. Alphatec Holdings, Inc. has a one year low of $8.69 and a one year high of $22.66. The company’s 50 day moving average price is $18.42 and its two-hundred day moving average price is $15.08.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The business had revenue of $196.50 million during the quarter, compared to analysts’ expectations of $182.78 million. During the same period last year, the company posted ($0.28) EPS. Alphatec’s revenue for the quarter was up 30.4% on a year-over-year basis. As a group, analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Trading of Alphatec

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd purchased a new position in Alphatec during the 3rd quarter valued at $34,000. Osterweis Capital Management Inc. purchased a new position in shares of Alphatec during the second quarter valued at approximately $37,000. Nisa Investment Advisors LLC boosted its position in shares of Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after purchasing an additional 1,045 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Alphatec in the 3rd quarter worth approximately $73,000. Finally, FORA Capital LLC bought a new position in Alphatec during the 1st quarter valued at approximately $102,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Morgan Stanley set a $23.00 price objective on Alphatec in a research note on Tuesday, December 2nd. Piper Sandler restated an “overweight” rating and set a $25.00 price target (up from $20.00) on shares of Alphatec in a research report on Friday, October 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a research note on Monday. Stifel Nicolaus began coverage on Alphatec in a research report on Tuesday, October 28th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Needham & Company LLC increased their price objective on Alphatec from $16.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Alphatec currently has an average rating of “Moderate Buy” and a consensus price target of $22.45.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.